Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834043 | 1.00 | GRIN2D (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29581345 | 0.87 | GRM4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29489477 | 0.87 | GRM4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17064311 | 0.87 | GRM4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18623225 | 0.87 | GRM4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL23429188 | 0.87 | GRM4 (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17064991 | 0.86 | TOP2A (0.37) | P4HBMAP2K1CA2CA9KIF11 | |
| SCHEMBL25667323 | 0.85 | ADRA1D (0.39) | HDAC1P4HBTNFADRA1DADRA1A | |
| SCHEMBL25667322 | 0.85 | ADRA1D (0.39) | HDAC1P4HBTNFADRA1DADRA1A | |
| SCHEMBL23429142 | 0.82 | S1PR1 (0.39) | GRM4P4HBTNFADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590069-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12552750-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545645-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545646-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12545647-B2 | Crystalline salts of a plasma kallikrein inhibitor | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250388547-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388545-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388546-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| US-20250388548-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-12-25 | — | — | US | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-13 | — | — | US | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-13 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| EP-3113772-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| CN-106257976-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2016-12-28 | — | — | CN | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545645-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | GRIN2D 3729/4885GRIN3B 3870/4885GRIN1 4323/4885 |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | GRIN2D 4562/4885GRIN3B 3024/4885GRIN1 3274/4885 |
| US-12545646-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | GRIN2D 3977/4885GRIN3B 3916/4885GRIN1 4408/4885 |
| US-20250388545-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | GRIN2D 3430/4885GRIN3B 3639/4885GRIN1 4384/4885 |
| US-20250388547-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | GRIN2D 3977/4885GRIN3B 3916/4885GRIN1 4408/4885 |
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | GRIN2D 4562/4885GRIN3B 3024/4885GRIN1 3274/4885 |
| US-12590069-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK2, KLK1 | GRIN2D 2318/4885GRIN3B 3586/4885GRIN1 4408/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | GRIN2D 4562/4885GRIN3B 3024/4885GRIN1 3274/4885 |
| US-12552750-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, F2, KLK1 | GRIN2D 2450/4885GRIN3B 3666/4885GRIN1 4265/4885 |
| US-20250388548-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | GRIN2D 2618/4885GRIN3B 3690/4885GRIN1 4404/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | GRIN2D 4562/4885GRIN3B 3024/4885GRIN1 3274/4885 |
| US-20250388546-A1 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK1, KLK2 | GRIN2D 3729/4885GRIN3B 3870/4885GRIN1 4323/4885 |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | GRIN2D 4562/4885GRIN3B 3024/4885GRIN1 3274/4885 |
| US-12545647-B2 | Crystalline salts of a plasma kallikrein inhibitor | KLKB1, KLK1, KLK2 | GRIN2D 2530/4885GRIN3B 3681/4885GRIN1 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.